Drugs / F/TDF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06560684 | Oct 2024 → Jun 2026 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F/TDF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06560684 ↗ |
| Route | Oral | “oral F/TDF 200 mg/300 mg sequence” NCT06560684 ↗ |